Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens
- Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02255-19. doi: 10.1128/AAC.02255-19.
- 1. College of Pharmacy, University of Illinois at Chicago, Rockford, Illinois, USA.
- 2. College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
- 3. College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA [email protected].
The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.